Estrone for PMDD
ESTRONE is annotated as a Phase 3 clinical candidate for PMDD acting as an estrogen receptor alpha agonist on ESR1.
Hypothesized mechanism
ESTRONE may modulate PMDD symptoms via agonism of estrogen receptor alpha (ESR1), influencing hormonally-mediated mood/affective pathways.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 3.8 of 10 overall, a emerging reading, from a pathway rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Female representation not stated — applicability to women uncertain (flagged for full text). (band F4, ×0.75).
Corroboration
Only a single line of evidence is present: an Open Targets annotation stating ESTRONE is an estrogen receptor alpha agonist clinical candidate for PMDD. No independent mechanistic lines converge to support the pathway.
Rigor
The claim derives from a curated database (Open Targets) citing a Phase 3 clinical stage, which implies human-relevant context, but no actual study model, data, or methodology is provided in the claim itself.
Specificity
The mechanism is precisely specified: estrogen receptor alpha agonist acting on the named target ESR1 (estrogen receptor 1), indicating a well-defined drug-target action.
Plausibility
Estrogen receptor signaling is mechanistically relevant to a hormonally-driven condition like PMDD, supporting plausibility, but the single annotation provides no phenotype-level data linking ERα agonism to symptom modulation.
Consistency
With only one claim, there are no conflicting signals, but neither is there corroborating directionality from multiple sources; consistency cannot be strongly established from a single annotation.
Regulatory & development status
Where this candidate sits in the US regulatory landscape: whether the drug is already FDA-approved for pmdd (on-label) or approved for something else (off-label), whether the molecule is available as a generic or a single-source brand still under patent, and how far it has been studied as a therapy for this condition. Each fact is drawn from a public US source and reported beside the score; none of it is folded into the score.
This is descriptive context, not regulatory advice. It maps the landscape a 505(b)(2)route would build on (an already-approved active ingredient proposed for a new indication), but it is not a 505(b)(2) viability assessment, and says nothing about whether any particular development path is advisable. “Approved” means FDA-approved (US); approvals elsewhere are out of scope.
Approval relationship No FDA-approved label
Read from the drug’s FDA label via DailyMed, the US National Library of Medicine’s label repository. A label is only counted when it carries an FDA-approved marketing category (an NDA, ANDA, or biologic BLA); dietary supplements, homeopathics, and OTC-monograph products are not FDA-approved drugs and are excluded.
For this pair. No FDA-approved drug label was found for this molecule (it may be a supplement, a biologic, investigational, or approved only outside the US), so any use here is investigational.
Generic & patent supply Discontinued
Read from the FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), using single-ingredient products only so that patents on novel branded combination formulations are never attributed to the base molecule.
For this molecule. Previously approved but no longer actively marketed in the Orange Book.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1Per Open Targets (retrieved 2026-06-16), ESTRONE (a Small molecule) is a clinical candidate for PMDD (maximum clinical stage PHASE_3); its mechanism of action is Estrogen receptor alpha agonist on target estrogen receptor 1. Open Targets · mechanistic ↗
- 2In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 11 report(s) of FATIGUE were recorded for ESTRONE among female patients (of 123 female reports for ESTRONE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests ESTRONE acts on a system relevant to PMDD — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
- 3In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 5 report(s) of DEPRESSION were recorded for ESTRONE among female patients (of 123 female reports for ESTRONE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests ESTRONE acts on a system relevant to PMDD — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
- 4In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 5 report(s) of INSOMNIA were recorded for ESTRONE among female patients (of 123 female reports for ESTRONE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests ESTRONE acts on a system relevant to PMDD — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →